Applied Therapeutics Shares Dive Following FDA Warning Letter Amid Positive Phase 3 Results

Introduction

APPLIED THERAPEUTICS INC (NASDAQ: APLT) is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases with high unmet medical need. As of November 13, 2025, its shares closed at $0.55, reflecting a 39.57% decline on a volume of 672,561 shares.

Corporate Structure

Headquartered in New York, New York, Applied Therapeutics employs between 11 and 50 people. The executive team possesses expertise in corporate development, chemistry, manufacturing and formulation, and operations. Key roles include Vice President of Chemistry, Manufacturing and Formulation, along with leadership in biopharma licensing and supply-chain strategy.

Biopharmaceuticals by CDC

Recent Developments and News

• November 13, 2025: The company filed its Form 10-Q for the quarter ended September 30, 2025, discussing ongoing investment in research and development.
• December 17, 2024: Two shareholder lawsuits were filed following a Complete Response Letter (CRL) and Warning Letter issued by the FDA on November 27, 2024. The Warning Letter, resulting from a May 2024 bioresearch monitoring inspection, cited dosing errors in the Phase 3 ACTION-Galactosemia Kids trial and data-integrity deficiencies.
• Ongoing Pipeline Milestones:
  • Govorestat (aldose reductase inhibitor) for SORD deficiency reported positive 12-month interim data from Phase 3.
  • Govorestat for PMM2-CDG advanced to Phase 2 readiness, with an Expanded Access program open.
  • AT-003 for diabetic retinopathy remains in Phase 1 readiness.
• September 2025: Company representatives participated in Charcot-Marie-Tooth (CMT) Awareness Month events in Denver and Boston, engaging with patient and advocacy communities.
• October 2025: Applied Therapeutics attended the American Society of Human Genetics (ASHG) Annual Meeting in Boston to discuss advances related to congenital disorders of glycosylation.

Financial and Strategic Analysis

In its November 13, 2025, 10-Q filing, Applied Therapeutics reported a cash position projected to be adequate to fund operations into 2026, with R&D expenditures making up a significant portion of operating expenses. The company continues to utilize structural biology and biomarker-driven strategies to advance clinical development. Compliance with FDA guidance on biomarker use supports efforts to expedite the approval process. However, the challenges presented by the CRL and Warning Letter introduce uncertainty regarding the timing of approvals for govorestat.

Market Position and Industry Context

Applied Therapeutics is positioned within the rare-disease therapeutics sector, where firms typically pursue accelerated approval pathways. By targeting validated molecular challenges such as aldose reductase and established clinical endpoints, the company aims to distinguish itself from competitors at earlier stages of drug discovery. The global market for orphan drugs is expanding as regulatory bodies and payers place importance on treatments for conditions that affect limited patient populations. Currently, no products have received regulatory approval, placing Applied Therapeutics among clinical-stage companies that are awaiting significant regulatory outcomes.

TL;DR

On November 13, 2025, Applied Therapeutics submitted its Q3 2025 10-Q, indicating continued R&D spending and a cash runway extending into 2026. The FDA’s November 27, 2024 CRL and Warning Letter—highlighting dosing errors and data-integrity issues—represent regulatory challenges for the govorestat NDA. Positive Phase 3 data for SORD deficiency supports future submissions, while shares traded at $0.55 (–39.57%) on NASDAQ:APLT in anticipation of upcoming FDA actions.